Isolated tumor rejection antigen precursor mage-2 derived peptid

Details Isolated tumor rejection antigen precursor mage-2 derived peptid Isolated tumor rejection antigen precursor mage-2 derived peptid

1998-01-15

2000-11-14

DiBrino, Marianne

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

11 to 14 amino acid residues in defined sequence

530328, 530350, A61K 3804, C07K 500

Patent

active

061471879

ABSTRACT:
The invention describes peptides derived from tumor rejection antigen precursor MAGE-2. These peptides bind with HLA-A2 molecules, thus presenting complexes which provoke cytolytic T cell production. The resulting "CTLs" are specific for complexes of HLA-A2 and the peptide. The complexes can be used to generate monoclonal antibodies. The cytolytic T cells produced may be used in the context of immunotherapy, such as adoptive transfer.

REFERENCES:
Falk et al. Nature, vol. 351, pp 290-296, 1991.
Bjorkman et al. Nature, vol. 329, pp 506-512, 1987.

Affiliated with

Also associated with

Rating

Isolated tumor rejection antigen precursor mage-2 derived peptid does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isolated tumor rejection antigen precursor mage-2 derived peptid, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isolated tumor rejection antigen precursor mage-2 derived peptid will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2066361